Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Miguel Coego Rios Is Appointed CFO of CENTOGENE

Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Miguel Coego Rios role as Managing Director and Chief Financial Officer of the Company, becomes effective June 22, 2022.

“As we continue to make progress on pivoting the organization to focus on Core Business execution, we are very fortunate to have someone of Miguel’s caliber and extensive experience to contribute to our financial leadership and success. With more than a decade of experience in senior finance roles in the biopharma sector, he will be instrumental as we cement our position as the essential biodata life science partner,” said Kim Stratton, CEO of CENTOGENE.

Miguel Coego Rios stated, “I am excited to formally assume the position as CFO of CENTOGENE. We have been working diligently to optimize operations and build a solid foundation to support our future strategic direction, which is expected to position the Company for growth in 2022 and beyond. My first priorities as the CFO will be business and shareholder value creation, ensuring financial health and best-in-class governance.”

Miguel Coego Rios joined CENTOGENE as EVP Finance & Legal in February 2022 and served as Interim Chief Financial Officer as of April 1, 2022. He is a seasoned senior executive and has previously served in finance and commercial leadership roles in the pharmaceutical and biotech sectors. Prior to joining CENTOGENE, Mr. Coego was Vice President & General Manager South Europe at Orphazyme A/S, a late-stage clinical biotech.

Before that he was Vice President & CFO EMEA at Mundipharma, a multinational pharmaceutical company. Earlier in his career, he served in several senior management positions at Shire Pharmaceuticals between 2011 and 2019, most recently as CFO LATAM and General Manager of the Andean region. Mr. Coego has gained notable international exposure having completed positions in Colombia, Brazil, Spain, and the U.K. He brings a proven track record in achieving sales and expense targets, company management and development, and leading multi-country projects to CENTOGENE.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine